ID   D-245MG
AC   CVCL_1152
SY   D-245 MG; D245 MG; D245MG
DR   ArrayExpress; E-MTAB-783
DR   cancercelllines; CVCL_1152
DR   Cell_Model_Passport; SIDM01021
DR   Cosmic; 946366
DR   Cosmic; 2367512
DR   Cosmic-CLP; 946366
DR   DepMap; ACH-002223
DR   GEO; GSM1669714
DR   IARC_TP53; 27553
DR   PRIDE; PXD030304
DR   Wikidata; Q54817123
RX   DOI=10.1007/0-306-46861-1_11;
RX   PubMed=2253244;
RX   PubMed=2881426;
RX   PubMed=3675803;
RX   PubMed=9220028;
RX   PubMed=10402232;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 44.10 hours (PubMed=2881426).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.72%; Native American=1.42%; East Asian, North=0.26%; East Asian, South=0.81%; South Asian=1.32%; European, North=65.72%; European, South=28.76% (PubMed=30894373).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): Cosmic-CLP=946366
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 12,13
ST   D16S539: 12
ST   D5S818: 13
ST   D7S820: 9,12
ST   TH01: 8,9
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=2253244;
RA   Bigner S.H., Humphrey P.A., Wong A.J., Vogelstein B., Mark J.,
RA   Friedman H.S., Bigner D.D.;
RT   "Characterization of the epidermal growth factor receptor in human
RT   glioma cell lines and xenografts.";
RL   Cancer Res. 50:8017-8022(1990).
//
RX   PubMed=2881426; DOI=10.1007/BF00687952;
RA   Bigner S.H., Friedman H.S., Biegel J.A., Wikstrand C.J., Mark J.,
RA   Gebhardt R., Eng L.F., Bigner D.D.;
RT   "Specific chromosomal abnormalities characterize four established cell
RT   lines derived from malignant human gliomas.";
RL   Acta Neuropathol. 72:86-97(1986).
//
RX   PubMed=3675803;
RA   Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.;
RT   "DNA content and chromosomes in permanent cultured cell lines derived
RT   from malignant human gliomas.";
RL   Anal. Quant. Cytol. Histol. 9:435-444(1987).
//
RX   PubMed=9220028; DOI=10.1016/S0303-7207(97)00080-4;
RA   Sharif T.R., Luo W., Sharif M.;
RT   "Functional expression of bombesin receptor in most adult and
RT   pediatric human glioblastoma cell lines; role in mitogenesis and in
RT   stimulating the mitogen-activated protein kinase pathway.";
RL   Mol. Cell. Endocrinol. 130:119-130(1997).
//
RX   PubMed=10402232; DOI=10.3892/ijo.15.2.237;
RA   Sharif T.R., Sharif M.;
RT   "Overexpression of protein kinase C epsilon in astroglial brain tumor
RT   derived cell lines and primary tumor samples.";
RL   Int. J. Oncol. 15:237-243(1999).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//